MarketCap
Facebook
X
TelegramAnnual report 2026
added 02-10-2026
Exelixis Cash Conversion Cycle 2011-2026 | EXEL
Annual Cash Conversion Cycle Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.32 | - | 5.31 | 68.5 | 66.8 | 14.4 | 59.3 | 61.7 | -5.2 | -355 | -304 | -649 | -2.06 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.5 | -2.06 K | -259 |
Quarterly Cash Conversion Cycle Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 | -1.54 | -35.5 | - | -65.7 | 12 | 5.34 | - | 49.3 | 45.1 | 43.4 | - | 77.3 | 128 | 110 | 78.1 | 81.3 | 88.8 | 92.4 | 54.1 | -53.6 | 83 | 28.1 | - | 75.7 | 41.8 | 53.2 | 65 | 52.7 | 63.6 | 5.03 | 38.2 | -6.26 | 74.8 | 68.6 | 77.4 | 96.6 | 102 | 135 | 47.6 | 48 | 59.2 | 48.9 | 60.6 | 70.8 | 67.9 | 82.1 | 82.7 | 65.8 | 30.3 | 31.6 | 32.1 | 18.9 | 32.1 | 6.78 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 135 | -65.7 | 50.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Harmony Biosciences Holdings
HRMY
|
20.4 | $ 27.99 | 4.17 % | $ 1.59 B |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.81 | 1.31 % | $ 4.42 M |  China |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Axsome Therapeutics
AXSM
|
-256 | $ 167.61 | -4.09 % | $ 8.34 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
337 | $ 194.87 | -0.75 % | $ 28.5 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
819 | $ 63.02 | 0.15 % | $ 12 B | USA |
 |
Baudax Bio
BXRX
|
-14.3 | - | 0.59 % | $ 63 K | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
123 | $ 14.72 | 2.08 % | $ 4.55 B | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |